GSK to acquire Experimental Myeloma Therapy

LONDON: GSK plc said Tueday it has agreed to acquire a potential best-in-class trispecific T cell-engager from Chimagen Biosciences, a privately held biotechnology company, for development and commercialization in multiple myeloma. The program is expected to enter Phase I trials in 2027. Under the…